Alpha 2-adrenoceptors and platelet function in patients with variant angina.
We have previously reported that platelets of patients with variant angina exhibited pronounced hyperactivity to epinephrine, as assessed by aggregation study. To determine whether this is associated with a change in surface alpha-adrenoceptor status, we investigated the capacity and affinity of binding sites for [3H]dihydroergocryptine, a potent alpha-antagonist, of platelet lysates prepared from 22 patients with ischemic heart disease and 13 control subjects of similar age. [3H]DHE binding capacity to platelets from control subjects, 6 patients with acute myocardial infarction, 9 with effort angina and 7 with variant angina were 233 +/- 44 (SD), 226 +/- 53, 252 +/- 58 and 348 +/- 48 fmol/mg protein and its affinity were 2.05 +/- 1.40, 0.98 +/- 0.46, 1.59 +/- 0.37 and 1.49 +/- 0.66 nM, respectively. The patients with variant angina had significantly higher capacity of platelet alpha-adrenoceptor than controls (49% increase) or patients with other types of ischemic heart disease. In contrast, the affinity for [3H]DHE was not significantly different as compared with other three groups. Similar increments in the binding capacity for [3H]-rauwolscine, alpha 2 antagonist, were found in platelet lysates prepared from 6 patients with variant angina. These results suggest that increased capacity of platelet alpha-adrenoceptor may explain enhanced reactivity to epinephrine in patients with variant angina.
Kusui
A
A
First Department of Internal Medicine, Kobe University School of Medicine, Japan.
Yokoyama
M
M
Fukuzaki
H
H
D000316:Adrenergic alpha-Agonists / Q000378:metabolism* / Q000494:pharmacology; D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000097:blood / Q000209:etiology; D000788:Angina Pectoris, Variant / Q000097:blood*; D001792:Blood Platelets / Q000032:analysis* / Q000187:drug effects; D003327:Coronary Disease / Q000097:blood; D003329:Coronary Vasospasm / Q000097:blood; D004088:Dihydroergotoxine / Q000378:metabolism; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood; D005082:Physical Exertion; D010974:Platelet Aggregation / Q000187:drug effects*; D011942:Receptors, Adrenergic, alpha / Q000378:metabolism*
D000316:Adrenergic alpha-Agonists; D011942:Receptors, Adrenergic, alpha; D004088:Dihydroergotoxine